Search clinical trials for: PLB1003

Total 27 results

Avistone Biotechnology Co., Ltd.

Recruiting

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Non-Small-Cell Lung Cancer

China
Beijing Pearl Biotechnology Limited Liability Company

Unknown

Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.

Non-Small Cell Lung Cancer

China
Avistone Biotechnology Co., Ltd.

Active, not recruiting

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Avistone Biotechnology Co., Ltd.

Active, not recruiting

Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Cancer

China
Beijing Pearl Biotechnology Limited Liability Company

Recruiting

A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) (KUNPENG)

Non-small Cell Lung Cancer

China
Avistone Biotechnology Co., Ltd.

Recruiting

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) (Kannon)

Non-Small-Cell Lung Cancer

China
Beijing Pearl Biotechnology Limited Liability Company

Active, not recruiting

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) (KUNPENG-2)

Non-small Cell Lung Cancer

China
Beijing Pearl Biotechnology Limited Liability Company

Completed

Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas

Glioma

China
Beijing Pearl Biotechnology Limited Liability Company

Completed

First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001

Non-Small Cell Lung Cancer

China
4B Technologies Limited

Not yet recruiting

A Study of FB1003 in Healthy Subject

Healthy Volunteers
PhaseBio Pharmaceuticals Inc.

Completed

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
PhaseBio Pharmaceuticals Inc.

Completed

Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

Diabetes Mellitus, Type 2

United States
Biotheus Inc.

Recruiting

Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors

Advanced Solid Tumors

China
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Seoul National University Hospital

Completed

Efficacy of PLEM100(Inbody®) in Children

Development, Child

Korea, Republic of
PhaseBio Pharmaceuticals Inc.

Completed

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Type 2 Diabetes Mellitus

United States
Beijing Pearl Biotechnology Limited Liability Company

Active, not recruiting

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

Glioblastoma

China
National Cancer Institute (NCI)

Completed

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Glioma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Oligodendrogliomas | Astrocytoma, Grades II, III and IV

United States
Avistone Biotechnology Co., Ltd.

Not yet recruiting

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Non-Small-Cell Lung Cancer
Lixte Biotechnology Holdings, Inc.

Unknown

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
GSK Pharma; Lixte

Recruiting

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Ovarian Clear Cell Carcinoma

United States
The Netherlands Cancer Institute

Not yet recruiting

LB-100 (PP2A Inhibitor) and Azenosertib (WEE1 Inhibitor) in Metastatic Colorectal Cancer Patients

Metastatic Colorectal Cancer
Lixte Biotechnology Holdings, Inc.

Completed

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Neoplasms | Cancer | Tumors

United States
The Netherlands Cancer Institute

Not yet recruiting

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients (CoLBAt)

Metastatic Microsatellite-stable Colorectal Cancer
PLx Pharma
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults

Erosion | Gastroduodenal Ulcerations

United States
Grupo Espanol de Investigacion en Sarcomas

Recruiting

Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer)

Advanced Soft-tissue Sarcoma

Spain
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer

Extensive Stage Lung Small Cell Carcinoma

United States

3

Subscribe